The New York Times featured Cenegenics in an article by journalist Tom Dunkel called “Vigor Quest.” Dunkel followed a 51-year-old Cenegenics patient, and explores hotly debated topics such as hormone optimization and male menopause. The article focuses on the difference between age management medicine’s proactive approach to middle-age malaise and mainstream medicine’s.
According to Michale J. “Mickey” Barber, MD, the CEO/CMO of Cenegenics Carolinas, our 2010 hormonal chemistry has been dictated by a millennium of evolution and is now outdated for today’s demands.
“Medical advances have us living until 70 or even 90, rather than the old 40-year benchmark. With that, we’re expected to perform at a 20-years’ younger level with this outdated endocrine chemistry. The medical profession is missing a key factor . . . why do we think our hormones should be suboptimal as we age? Years ago, the medical profession thought 70 year olds should tolerate a higher blood
pressure and higher LDL level than their 30-something counterparts. Now, of course, we treat those older persons to have blood pressure and LDL levels equivalent to the 30 year old,” Barber said.
“Vigor Quest” explores both sides of this often controversial field of medicine, and raises compelling arguments for age management medicine naysayers.
Read the Full Article: Vigor Quest
Read the Press Release: NY Times Investigates Baby Boomer Vigor Quest & Cenegenics.
For more information or to schedule a comprehensive health evaluation, please call (843) 577-8484.
